Skip to content
Open access

SNORA23-KDM5C epigenetic axis mediates dual DNA repair pathways to drive radioresistance in esophageal squamous cell carcinoma.

Jul 2026 · Cell Death and Differentiation · 0 citations · 42 references
Medicine

TL;DR

A snoRNA-chromatin-repair axis driving therapeutic resistance and support SNORA23 inhibition as a promising strategy to overcome radioresistance in ESCC are defined.

Abstract

Radioresistance remains a major barrier in esophageal squamous cell carcinoma (ESCC). This study demonstrates small nucleolar RNA SNORA23 as a pathogenic epigenetic driver of intrinsic radioresistance, with its overexpression tightly correlating with advanced T-stage, lymph node metastasis, and adverse clinical outcomes in a chemoradiotherapy cohort. Mechanistically, SNORA23 directly binds the ARID domain of histone demethylase KDM5C via a structurally defined G11-Ser169 interface-obstructing KDM5C chromatin binding to derepress DNA repair scaffolding gene SFPQ. This chromatin reprogramming enables SFPQ-facilitated recruitment of RAD51 and Ku80 to DNA double-strand breaks, accelerating homologous recombination (HR) and non-homologous end joining (NHEJ). SFPQ high expression recapitulates SNORA23-mediated repair enhancement and reduced radiosensitivity. Therapeutically, SNORA23-targeting antisense oligonucleotides (ASOs) disrupt this axis, impair DNA repair, and synergize with radiotherapy to suppress tumor growth and prolong survival in vivo without evident systemic toxicity These findings define a snoRNA-chromatin-repair axis driving therapeutic resistance and support SNORA23 inhibition as a promising strategy to overcome radioresistance in ESCC.

Read PDF

Similar papers

Open access Sep 2026

DDX21 Enhances Radiosensitivity in Head and Neck Squamous Cell Carcinoma by Suppressing MK2‐Mediated DNA Damage Response

ABSTRACT Radioresistance remains a significant challenge in the radiotherapy (RT) of head and neck squamous cell carcinoma (HNSCC). However, the biological factors that govern sensitivity to this therapy are not well‐understood. The DEAD‐box family is known for its role in genome stability, and inextricably linked to t...

Tian-Ru Yang, T. Shen, Yan-Fang Qiu et al. · 0 citations
Open access Aug 2026

KAT8‐Low Osteosarcoma Suppresses Cisplatin Sensitivity via H4K16ac‐Mediated Cell Apoptosis

The hypothesis emphasizes the need to clarify the molecular mechanisms and signaling pathways associated with KAT8–H4K16ac, especially in relation to apoptotic pathways, which could offer new insights and justifications for treatment strategies in cisplatin‐resistant osteosarcoma.

Zhen-Qun Zhao, Guohui Yu, Shi-Kui Wu et al. · 0 citations
Open access Sep 2026

Androgen receptor condensates drive gastric cancer through SWI/SNF-mediated chromatin remodeling and create a therapeutic vulnerability

These findings establish AR phase separation as a fundamental mechanism driving GC pathogenesis and propose co-targeting AR condensates and chromatin remodeling as a translatable therapeutic strategy.

Hua-Huan Liu, Yan-Xin Yao, Xiang-Nan Zhang et al. · 0 citations
Sep 2026

SEPT5 confers radioresistance by suppressing GSDME-dependent pyroptosis and antitumor immunity in non-small cell lung cancer.

An integrated mechanism in which SUMOylation-dependent stabilization of SEPT5 and UBE3B-mediated GSDME degradation converge to suppress pyroptosis and attenuate antitumor immunity is defined, positioning the SEPT5 regulatory axis as a potential therapeutic vulnerability to overcome radioresistance and enhance the effic...

Jun-Miao Wen, Wang Zheng, Bo-Yan Wang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.